HETERO LABS LIMITED
Location
Telangana
Founded
1989-03-10
Website
Risk Signals
265 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about HETERO LABS LIMITED
Live alerts from global media, monitored by Business Radar
2020-05-15 (biospectrumindia.com)
"Hetero is working to bring Remdesivir for COVID-19 treatment"- Dr. B P S Reddy
Dr. B. Partha Saradhi Reddy, Chairman, Hetero Group of Companies, Hyderabad talks about how his company is contributing in fighting the pandemic
Read more
(indiatimes.com)
Lenacapavir: Dr Reddy's and Hetero Align with Gilead for Landmark HIV Drug Licensing Agreement
Dr Reddy's Laboratories and Hetero sign non-exclusive, royalty-free agreements with Gilead Sciences to manufacture Lenacapavir for HIV treatment in India and 120 LMICs, enhancing access for heavily treatment-experienced adults. The agreement paves the way for rapid introduction of generic versions for HIV prevention.
Read more